Plasticity of AMPA and NMDA receptor-mediated epileptiform activity in a chronic model of temporal lobe epilepsy

1995 ◽  
Vol 21 (2) ◽  
pp. 95-107 ◽  
Author(s):  
Christophe Bernard ◽  
Howard V. Wheal
NeuroImage ◽  
2001 ◽  
Vol 13 (6) ◽  
pp. 153
Author(s):  
Sven Hoegg ◽  
Hans-Jürgen Huppertz ◽  
Christian Sick ◽  
Josef Zentner ◽  
Andreas Schulze-Bonhage ◽  
...  

Antioxidants ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1702
Author(s):  
Sereen Sandouka ◽  
Tawfeeq Shekh-Ahmad

Epilepsy is a chronic disease of the brain that affects over 65 million people worldwide. Acquired epilepsy is initiated by neurological insults, such as status epilepticus, which can result in the generation of ROS and induction of oxidative stress. Suppressing oxidative stress by upregulation of the transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) has been shown to be an effective strategy to increase endogenous antioxidant defences, including in brain diseases, and can ameliorate neuronal damage and seizure occurrence in epilepsy. Here, we aim to test the neuroprotective potential of a naturally occurring Nrf2 activator sulforaphane, in in vitro epileptiform activity model and a temporal lobe epilepsy rat model. Sulforaphane significantly decreased ROS generation during epileptiform activity, restored glutathione levels, and prevented seizure-like activity-induced neuronal cell death. When given to rats after 2 h of kainic acid-induced status epilepticus, sulforaphane significantly increased the expression of Nrf2 and related antioxidant genes, improved oxidative stress markers, and increased the total antioxidant capacity in both the plasma and hippocampus. In addition, sulforaphane significantly decreased status epilepticus-induced neuronal cell death. Our results demonstrate that Nrf2 activation following an insult to the brain exerts a neuroprotective effect by reducing neuronal death, increasing the antioxidant capacity, and thus may also modify epilepsy development.


2014 ◽  
Vol 125 ◽  
pp. S170-S171
Author(s):  
J.A. Bragatti ◽  
I.C. Bandeira ◽  
A.M. Carvalho ◽  
P.A. Cherubini ◽  
C.M. Torres ◽  
...  

Epilepsia ◽  
2020 ◽  
Vol 61 (5) ◽  
Author(s):  
Nagisa Sada ◽  
Shogo Suto ◽  
Mana Suzuki ◽  
Shoichiro Usui ◽  
Tsuyoshi Inoue

Epilepsia ◽  
2010 ◽  
Vol 51 (9) ◽  
pp. 1754-1762 ◽  
Author(s):  
Stéphanie Graebenitz ◽  
Jörg Lesting ◽  
Ludmila Sosulina ◽  
Thomas Seidenbecher ◽  
Hans-Christian Pape

2018 ◽  
Author(s):  
Richard G. Sanchez ◽  
R. Ryley Parrish ◽  
Megan Rich ◽  
William M. Webb ◽  
Roxanne M. Lockhart ◽  
...  

AbstractTemporal Lobe Epilepsy (TLE) is frequently associated with changes in protein composition and post-translational modifications (PTM) that exacerbate the disorder. O-linked-β-N-acetyl glucosamine (O-GlcNAc) is a PTM occurring at serine/threonine residues that integrate energy supply with demand. The enzymes O-GlcNActransferase (OGT) and O-GlcNAcase (OGA) mediate the addition and removal, respectively, of the O-GlcNAc modification. The goal of this study was to determine whether changes in OGT/OGA cycling and disruptions in protein O-GlcNAcylation occur in the epileptic hippocampus. We observed reduced global and protein specific O-GlcNAcylation and OGT expression in the kainate rat model of TLE and in human TLE hippocampal tissue. Inhibiting OGA with Thiamet-G elevated protein O-GlcNAcylation, and decreased both seizure duration and epileptic spike events, suggesting that OGA may be a therapeutic target for seizure control. These findings suggest that loss of O-GlcNAc homeostasis in the kainate model and in human TLE can be reversed via targeting of O-GlcNAc related pathways.


Sign in / Sign up

Export Citation Format

Share Document